Global Hepatocellular Carcinoma Drugs Market – Industry Trends and Forecast to 2027

Global Hepatocellular Carcinoma Drugs Market By Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2027

Market Analysis: Global Hepatocellular Carcinoma Drugs Market
Global hepatocellular carcinoma drugs market is rising gradually with the steady CAGR of 3.9% in the forecast period of 2020-2027. The report consists of base year 2019 and historic year 2018. Ongoing strong pipeline for hepatocellular carcinoma by several companies will bring a great opportunity for the market growth.

Market Definition: Global Hepatocellular Carcinoma Drugs Market
Hepatocellular carcinoma (HCC) is the most common type of primary malignancy in liver. The major causes of this type of liver cancer are chronic liver diseases including cirrhosis caused by hepatitis B and hepatitis C. The prevalence of HCC has evolved significantly over the past few decades and it has become the third leading cause of deaths by cancer worldwide. Due to high prevalence of hepatitis B and hepatitis C chronic liver diseases are increasing, the incidence of HCC is more in Asia and Africa, as compared to Africa and Asia, the incidence of HCC is highest in Asia, with incidence rates in men of 35 per 100,000 populations.

Leave a Reply

Your email address will not be published. Required fields are marked *